About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Lymphoma Clinical Trials in Ohio | 757 Studies

Clinical Trials LymphomaOhio

Lymphoma Clinical Trials in Ohio

Find 757 clinical trials for lymphoma near Ohio. Connect with research centers in your area.

All Lymphoma trials nationwide All trials in Ohio

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 481-500 of 757 trials

RecruitingA Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell MalignanciesThis Phase 1, open-label, multicenter study is evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of lonitoclax…NCT06708897·Louisville, Kentucky and 4 others TerminatedLenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell LymphomaA Phase IB/II Trial of Lenalidomide (Revlimid®), Ixazomib and Rituximab (RIXAR) as Front-line Therapy for High Risk Indolent B cell LymphomaNCT02898259·Cleveland, Ohio and 1 other CompletedRituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to RituximabMonoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.NCT00238238·La Jolla, California and 78 others

PreviousPage 25 of 38Next

Lymphoma Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

CompletedAcalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell LymphomaTo characterize the safety profile of acalabrutinib in subjects with relapsed or refractory de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma (DLBCL).NCT02112526·Los Angeles, California and 6 others

TerminatedA Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or LymphomaThe Phase 1 portion of this study will determine the safety of TAS4464 and the most appropriate dose for patients with Multiple Myeloma or Lymphoma.NCT02978235·Bethesda, Maryland and 6 others

RecruitingA Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or…NCT06022029·Los Angeles, California and 15 others

TerminatedQUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With RituximabThis is a Phase I/II, open-label, multi-center, competitive enrollment and dose escalation study of N-803 in patients with relapse/refractory indolent B cell non-Hodgkin lymphoma…NCT02384954·Minneapolis, Minnesota and 3 others

TerminatedA Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque PsoriasisThe main objective of this study is to evaluate the long-term safety of CP-690,550 in patients being treated for moderate to severe chronic plaque psoriasis.NCT01163253·Birmingham, Alabama and 322 others

CompletedComparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell TransplantThe purpose of this study is to evaluate the efficacy of Pixantrone + Rituximab compared to Gemcitabine + Rituximab in patients with relapsed or refractory diffuse large B-cell…NCT01321541·Tucson, Arizona and 130 others

RecruitingTesting the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell LymphomaThis phase II trial tests how well venetoclax, ibrutinib, prednisone, obinutuzumab, and Revlimid® (ViPOR) works in treating patients with CD10 negative diffuse large B-cell…NCT06649812·Tucson, Arizona and 103 others

Approved for marketingAxicabtagene Ciloleucel Expanded Access StudyA multicenter, open-label expanded access protocol for the treatment of subjects with relapsed/refractory large B-cell lymphoma.NCT03153462·Duarte, California and 14 others

CompletedDose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid MalignanciesA two part, Phase 1b/2 study to define a recommended Phase 2 dose of VRx-3996 in combination with valganciclovir (Phase 1b) designed to evaluate the efficacy of this combination…NCT03397706·Los Angeles, California and 27 others

CompletedCombination Chemotherapy in Treating Patients With AIDS-Related Hodgkin's DiseaseRATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.NCT00003114·Cleveland, Ohio

TerminatedComparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's LymphomaThe purpose of this study is to determine whether combining pixantrone (BBR 2778, INN name pending) with the monoclonal antibody rituximab, leads to an increase in the period of…NCT00060671·Tucson, Arizona and 37 others

TerminatedPhase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLLIMMU-114 will be studied at different dose schedules and dose levels in order to assess the highest dose safely tolerated.NCT01728207·Newark, Delaware and 4 others

Active not recruitingErdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)This phase II Pediatric MATCH trial studies how well erdafitinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with FGFR mutations…NCT03210714·Birmingham, Alabama and 115 others

TerminatedEfficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic DermatitisThe primary objective of the study is to assess the efficacy of REGN3500 monotherapy in Atopic dermatitis (AD), as well as understand the dose-response relationship, compared with…NCT03738423·Birmingham, Alabama and 88 others

CompletedDonor Stem Cell Transplant in Treating Patients With Hematologic CancerRATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral stem cell transplant helps stop the growth of cancer and abnormal cells and helps stop the…NCT00054327·Cleveland, Ohio

Active not recruitingIntrathecal Rituximab With Standard Intrathecal Prophylaxis to Prevent CNS Relapse for CD 20+ Non Hodgkin LymphomaThe purpose of this research study is to learn if giving rituximab, the study drug, right into the spinal canal along with chemotherapy drugs like methotrexate is possible and…NCT03688451·Cincinnati, Ohio

CompletedBortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell LymphomaThis phase II trial studies how well bortezomib and lenalidomide work in treating patients with mantle cell lymphoma that has come back after a period of improvement (refractory)…NCT00553644·Anaheim, California and 81 others

Other Conditions in Ohio

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia